Takeda Broadens Diabetes Pipeline With PPD Agreement For DPP4 Inhibitors
This article was originally published in The Pink Sheet Daily
Executive Summary
Takeda completes acquisition of development and marketing rights to PPD’s dipeptidyl peptidase IV inhibitors for treatment of type 2 diabetes. PPD will provide clinical development services. The deal follows the discontinuation of Takeda’s in-house novel diabetes agent due to liver abnormalities.